Drugs / QT-219C
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07507201 | Apr 2026 → Dec 2028 expected | IgA glomerulonephritis, anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic multidrug-resistant nephrotic syndrome, systemic lupus erythematosus +1 | The Children's Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT07530380 | Apr 2026 → Dec 2029 expected | autoimmune hemolytic anemia, warm type, uridine-cytidineuria | The Second Hospital of Anhui Medical University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QT-219C | “This is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C.” NCT07507201 ↗ |
| Action | Deplete | “the therapy aims to achieve deep and extensive depletion of pathogenic immune cells” NCT07507201 ↗ |
| Modality | Cell therapy | “QT-219C is a universal allogeneic chimeric antigen receptor T-cell (CAR-T) product” NCT07507201 ↗ |
| Route | Intravenous | “a single intravenous infusion of QT-219C” NCT07507201 ↗ |
| Target | CD19 | “targeting both CD19 and BCMA” NCT07507201 ↗ |